Posted inBiotechnology
TDP-43 PET Ligands: Advancing Proteinopathy Diagnosis
In recent years, the elusive nature of TDP-43 proteinopathies has challenged neuroscientists and clinicians alike, particularly in the quest to…
Posted inBiotechnology
Rab5 GTPases Direct ROP Signaling for Pollen Polarity
In the realm of cellular biology, the establishment of polarity stands as a cornerstone of eukaryotic life. This process, which…
Posted inBiotechnology
New Brain PET Tracer Targets TDP-43 Pathology
In a groundbreaking advancement poised to reshape neurodegenerative disease diagnostics, researchers have introduced [^18F]ACI-19626, a pioneering brain PET tracer designed…
Posted inBiotechnology
Evaluating Chinese Nurses’ Sexual Harassment Scale Validity
In a groundbreaking study recently published in BMC Nursing, researchers led by Q. Zhang, X. Chen, and H. Cao have…
Posted inBiotechnology
Engineered Metarhizium Fungi Lure and Kill Mosquitoes
In the ongoing battle against mosquito-borne diseases, traditional chemical insecticides have long been the first line of defense. However, the…
Posted inBiotechnology
Harnessing T Cell Potential: Oxford Researchers Chart the Future of Cancer Immunotherapy
In the relentless battle against cancer, T cells have emerged as pivotal warriors within the adaptive immune system. These specialized…
Posted inBiotechnology
Eli Lilly buys cash-strapped Adverum for its phase 3-stage eye disease gene therapy
Just as Adverum’s cash reserves were running dry, Eli Lilly has swooped in to buy the biotech and its phase…
Posted inBiotechnology
Hemab, working to build ‘ultimate clotting company,’ raises $157M series C for bleeding disorder ambitions
With a $157 million series C funding round, Hemab Therapeutics is looking to infuse innovation into the treatment landscape for…
Posted inBiotechnology
Evaluating Orbicularis Oculi’s Role in Eyelid Function
Emerging research in the field of ophthalmology has recently spotlighted the intricate functions of the lower eyelid musculature, particularly focusing…
Posted inBiotechnology
Biogen beefs up immunology pipeline with $1B deal for Vanqua’s preclinical C5aR1 antagonist
Biogen plans to beef up its early-stage immunology pipeline by handing over $70 million in upfront cash for the rights…